Share on StockTwits

Equities research analysts at Bank of America assumed coverage on shares of Pacira Pharmaceuticals (NASDAQ:PCRX) in a research note issued to investors on Monday, AnalystRatingsNetwork reports. The firm set a “buy” rating on the stock.

A number of other analysts have also recently weighed in on PCRX. Analysts at Piper Jaffray upgraded shares of Pacira Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Tuesday, April 1st. They now have a $84.00 price target on the stock, up previously from $75.00. Analysts at National Alliance Securities initiated coverage on shares of Pacira Pharmaceuticals in a research note on Tuesday, March 18th. They set a “buy” rating and a $109.41 price target on the stock. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $71.90.

Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 2.60% on Monday, hitting $67.77. 61,392 shares of the company’s stock traded hands. Pacira Pharmaceuticals has a 52-week low of $24.70 and a 52-week high of $83.41. The stock’s 50-day moving average is $70.64 and its 200-day moving average is $60.6. The company’s market cap is $2.285 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings data on Tuesday, February 25th. The company reported ($0.33) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.31) by $0.02. Analysts expect that Pacira Pharmaceuticals will post $-0.43 EPS for the current fiscal year.

Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.